 |
| |
|
IGF-I (Myotrophin) in ALS
|
| |
Sponsor |
| |
|
Great Lakes ALS Consortium |
| |
Principal Investigator |
| |
|
Eric Sorenson, MD
Mayo Clinic, Rochester, Minnesota |
| |
Berman Center Site Investigator |
| |
|
William David, MD, PhD |
| |
Berman Center Coordinator |
| |
|
Shirley
Conn, RN
612-341-7907 |
| |
Description |
| |
|
This project, which will enroll 330 ALS patients
at 17 clinical sites across the U.S., tests the efficacy of the
investigational drug IGF-I (Insulin-like Growth Factor) for slowing
the progression of ALS. IGF-I is a growth factor that has shown
promise in protecting the motor neurons in the brain and spinal
cord. The study is a double-blinded, placebo-controlled trial in
which intervention lasts for 24 months. Participants inject the
treatment twice daily for 24 months. |
| |
Role of the Berman Center |
| |
|
The Berman Center conducts 5 study visits and
3 study telephone calls during the 24-month follow-up period. At
the study visits, Berman Center doctors, research nurses, and physical
and respiratory therapists will do blood tests, qualitative muscles
tests, a forced vital capacity test, and weight and vital sign
measurement. This study is closed to enrollment. |
| |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
 |
 |
